The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort by D. Kawakita et al.
The impact of folate intake on the risk of head
and neck cancer in the prostate, lung,
colorectal, and ovarian cancer screening trial
(PLCO) cohort
Daisuke Kawakita*,1,2,3,4, Yuan-Chin Amy Lee1,2, Lisa H Gren1,2, Saundra S Buys2,5, Carlo La Vecchia6
and Mia Hashibe1,2
1Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City,
UT 84108, USA; 2Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT 84108, USA; 3Department of
Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8602,
Japan; 4Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan;
5Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT 84108, USA and 6Department of
Clinical Sciences and Community Health, Universita` degli Studi di Milano, Milan 520133, Italy
Background: Although low levels of folate leads to disturbances in DNA replication, DNA methylation and DNA repair, the
association between dietary folate intake and head and neck cancer (HNC) risk remains unclear.
Methods: We evaluated the association between folate intake and HNC risk using prospective cohort data from the Prostate,
Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. This study included 101 700 participants and 186 cases with confirmed
incident HNC. The median follow-up was 12.5 years. We estimated hazard ratios (HRs) and the corresponding 95% confidence
intervals (CIs) using Cox proportional hazard model including age, sex, body mass index, education, race, tobacco smoking,
alcohol drinking and total fruit and vegetable intake.
Results: Higher intake of food folate and fortified folic acid in foods was associated with a decreasing HNC risk in a dose–
response manner. The HRs of highest vs the lowest quartile of intake were 0.35 (95%CI: 0.18–0.67) for food folate, and 0.49 (95%CI:
0.30–0.82) for fortified folic acid. Intakes of total folate, natural folate and supplemental folic acid were not associated with the risk
of HNC and its subsites. We did not detect any interaction between smoking, drinking and food folate intake on HNC risk.
Conclusions: These findings provide evidence of the protective role of dietary folate intake on HNC risk.
In the United States, over 60 000 new head and neck cancer (HNC)
cases was diagnosed, with over 16 000 patients dying from HNC in
2016, and this is the sixth most common cancer among men (Siegel
et al, 2016). Tobacco smoking, alcohol drinking and human
papilloma virus (HPV) infection for oropharyngeal cancer are
established risk factors (Hashibe et al, 2009; Lubin et al, 2009;
Marur et al, 2010). However, the role of other environmental
factors, including dietary factors, remains unclear.
Fruit and non-starchy vegetables, which are rich in minerals,
antioxidants, and vitamins including folate, may decrease HNC
risk (Pavia et al, 2006; Freedman et al, 2008; Lucenteforte et al,
2009). Folate is a water-soluble vitamin of the B complex group
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and plays a definite role in one-carbon metabolism, which
facilitates de novo deoxynucleoside triphosphate synthesis and
provides methyl groups required for intracellular methylation
reactions (Lamprecht and Lipkin, 2003). Since folate insufficiency
leads to disturbances in DNA replication, DNA methylation and
DNA repair (Duthie, 1999; Kim, 1999; Choi and Mason, 2002),
deficiency of folate intake may increase the risk of HNC. This issue
has been evaluated by several epidemiological studies (McLaughlin
et al, 1988; De Stefani et al, 1999; Negri et al, 2000; Weinstein et al,
2002; Bidoli et al, 2003; Pelucchi et al, 2003; Suzuki et al, 2007;
Shanmugham et al, 2010; Aune et al, 2011; Tavani et al, 2012;
Galeone et al, 2015), including one large-scale pooled-analysis
(Galeone et al, 2015). Most studies reported that higher folate
intake was associated with a decreased HNC risk (Negri et al, 2000;
Weinstein et al, 2002; Bidoli et al, 2003; Pelucchi et al, 2003; Suzuki
et al, 2007; Shanmugham et al, 2010; Aune et al, 2011; Tavani et al,
2012; Galeone et al, 2015) except for two studies (McLaughlin et al,
1988; De Stefani et al, 1999). Most investigations were case-control
studies except for the Nurse’s Health Study (Shanmugham et al,
2010), which however considered only the alcohol–folate interac-
tion. Therefore, further evidence and quantification from cohort
studies would aid the understanding of the relationship between
folate and HNC risk.
In this study, we evaluated the association between folate intake
and the risk of HNC using observational prospective data from the
Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening
trial (Prorok et al, 2000).
MATERIALS AND METHODS
Study design and subjects. The PLCO cancer screening trial is a
large-scale clinical trial designed to determine whether selected
screening tests reduce deaths from prostate, lung, colorectal, and
ovarian cancer (Prorok et al, 2000). The trial started in 1992 and
ended enrolment in 2001. Approximately 155 000 participants
between the ages of 55 and 74 were enrolled at 10 centres across
the United States (Alabama, Michigan, Colorado, Hawaii,
Wisconsin, Minnesota, Pennsylvania, Utah, Missouri, and
Washington DC). Participants were individually randomised to
the control arm or intervention arm in equal proportions.
Participants assigned to the control arm received usual care,
whereas participants assigned to the intervention arm were invited
to receive screening exams for prostate, lung, colorectal, and
ovarian cancers. Screening of participants ended in late 2006.
Follow-up continues for up to 10 more years to determine the
benefits or harms of screening tests. Written informed consent was
obtained from all study participants. Ethical approval for human
subject’s research was obtained at each of the centres.
Assessment of lifestyle factors and head and neck cancer
confirmation. Subjects randomised to either study arm (control
or intervention) were eligible if they had completed the baseline
questionnaire and the diet history questionnaire, which was
administered to participants in both arms between 1998 and
2005 (Subar et al, 2000). A study update was mailed yearly to
participants to ascertain and confirm cancer diagnoses. Partici-
pants were asked if they were diagnosed with cancer, which kind of
cancer, date of diagnosis, hospital or clinic of diagnosis, and
physician contact information. For every cancer reported, medical
record abstraction included the cancer diagnosis date and the
International Classification of Disease for Oncology, second
version (ICD-O-2) code. Vital status was obtained by the
administration of the Annual Study Update questionnaire, reports
from relatives, friends, or physicians, and National Death Index
plus searches. The study centres attempted to obtain a death
certificate for each death. If participants were diagnosed with
cancer after study entry, which ranged from 1992 to 2001, and
before completion of the dietary questionnaire, they were not
eligible. HNC cases were diagnosed from enrolment completion to
December 2009, the last available follow-up. Only malignant
primary HNC cases were considered in the present analysis.
Tumours were assigned to one of the five categories as follows: (1)
oral cavity: ICD-O-2 codes C00.3 to C00.9, C02.0 to C02.3, C03.0,
C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0 to C06.2,
C06.8, and C06.9; (2) oropharynx: ICD-O-2 codes C01.9, C02.4,
C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0, C10.2-C10.4,
C10.8, and C10.9; (3) hypopharynx: ICD-O-2 codes C12.9, C13.0
to C13.2, C13.8, and C13.9; (4) oral cavity or pharynx not
otherwise specified (NOS): ICD-O-2 codes C02.8, C02.9, C05.8,
C05.9, C14.0, C14.2, and C14.8; and (5) larynx: ICD-O-2codes
C10.1, C32.0 to C32.3 and C32.8 to C32.9. Of the 154 897
participants recruited into the PLCO study, 111 488 participants
completed both the baseline questionnaire and the diet history
questionnaire. Of the 111 488 participants with valid question-
naires, participants were excluded because: (1) they had cancer
before entry into the PLCO study (n¼ 9697); (2) they did not have
follow-up time (n¼ 91). Thus, this study included 101 700
participants, and 186 cases with confirmed incident HNC.
For HNC cases, the numbers for control vs intervention group
were: 93 vs 93.
The baseline questionnaire included information on age, sex,
race, education, tobacco smoking, alcohol drinking, family history
of cancer, medical history, weight, height and other selected
lifestyle factors. Dietary data were collected using a self-
administered food-frequency questionnaire, the Diet History
Questionnaire, version 1.0 (National Cancer Institute, 2017),
which was distributed to the control and intervention arms of
the trial between 1998 and 2005 (Subar et al, 2000). The diet
history questionnaire included portion size and frequency of
consumption of 124 food item and supplement use during the past
year (National Cancer Institute, 2017). Folate intake was estimated
in accordance with the following five sources (Oaks et al, 2010):
(1) natural folate (polyglutamates found naturally in food), (2)
fortified folic acid (folic acid added to food), (3) food folate
(a combination of natural folate and fortified folic acid), (4)
supplemental folic acid (folic acid from vitamin supplements), and
(5) total folate intake (a combination of food folate and
supplemental folic acid). Food folate content was based on pre-
folic acid fortification (1998) database information from the 1994–
1996 Continuing Survey of Food Intake by Individuals (Subar et al,
1995). The post-folic acid grain fortification database information
from the Nutrition Data System for Research (NDS-R) was used to
estimate folic acid from fortified food. The NDS-R combines
nutrition information from the US Department of Agriculture
Nutrient Database for Standard Reference, food manufacturers,
scientific literature, and other published food tables (University of
Minnesota Nutrition Co-ordinating Center, NDSR descriptive
overview). Supplemental folic acid use and dose were derived from
recent use (current or 2 year ago) of four multivitamins (Oaks et al,
2010): One-a-Day (100% of the Recommended Dietary Allowance;
Bayer Corp, Pittsburgh, PA, USA), a therapeutic or high-dose type
(4100% of the Recommended Dietary Allowance; e.g., Theragran;
Bristol-Myers Squibb, New York, NY, USA), Stresstabs (B-
complexþ vitamin C; Inverness Medical Inc, Waltham, MA,
USA), and B-complex. The B-complex multivitamin was assigned
a 200-mcg folic acid dose, whereas the other multivitamins were
assigned a 400-mcg folic acid dose.
Statistical analysis. Follow-up time was calculated from the date
of entry until the occurrence of one of the following events:
diagnosis of HNC, death, or the end of follow-up. We estimated
hazard ratios (HRs) and the corresponding 95% confidence
intervals (CIs) of HNC and its subsites for quartile categories of
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folate intake using the Cox proportional hazards model. Models
included adjustment for age (categorical), sex, body mass index
(BMI) at interview (p24.9 kgm 2 vs X25 kgm 2), education
(phigh school vs Xsome college), race (White, non-Hispanic vs
Other), pipe and cigar smoking status (never vs former vs current),
pack-year cigarette smoking (never vs o20 vs X20), alcohol
drinking intensity (never vs o4.1 g per day vs X4.1 g per day),
non-alcohol total energy (continuous), and total fruit and vegetable
intake (continuous). To test interactions, we performed likelihood-
ratio tests, which compared models with and without the
interaction term.
All statistical analyses were performed using the software
STATA version.13 (Stata Corp, College Station, TX, USA). All tests
were two-sided.
RESULTS
The median follow-up was 12.5 years. Table 1 shows the
characteristics of the PLCO cohort and the HNC cases. Higher
proportions of male, smokers, and drinkers were found in the
HNC cases. Other characteristics showed no appreciable difference
between the cohort and the HNC cases. The HNC cases consisted
of 81 cases of oral cavity, 18 of oropharynx, 10 of hypopharynx, 1
of NOS, and 76 of larynx.
Table 2 gives the multivariate HRs, and the corresponding 95%
CI for the various sources of folate intake on the risk of HNC and
its subsites. Higher intake of food folate and fortified folic acid was
associated with a decreased HNC risk in a dose–response manner.
The HRs of highest vs the lowest quartile of intake were 0.35 (95%
CI: 0.18–0.67) for food folate, and 0.49 (95% CI: 0.30–0.82) for
fortified folic acid. Although these trends were consistent in
laryngeal cancer cases, the impact of food folate or fortified folic
acid were weaker than that for oral cavity and pharyngeal cancer
cases, especially for fortified folic acid. Intakes of total folate,
natural folate, and supplemental folic acid were not observed to be
associated with the risk of HNC and its subsites, though all the
HRs were below unity.
We also evaluated interactions of cigarette smoking and alcohol
drinking with food folate intake on HNC risk (Figures 1 and 2).
We found no significant deviation from the multiplicative model
between smoking, drinking, and food folate intake on HNC risk
(Figure 1: pinteraction for smoking¼ 0.471; Figure 2: pinteraction for
drinking¼ 0.395). In a multivariate analysis, the HR of high
tobacco/low food folate intake vs no tobacco/high food folate
intake was 22.09, and high alcohol/low food folate intake vs no
alcohol/high food folate intake was 3.57. Additionally, we
performed stratified analyses between selected confounders and
food folate intake on HNC risk (Figure 3). Food folate intake did
not show remarkable heterogeneity by potential confounders,
including age, sex, BMI and education, on HNC risk.
DISCUSSION
In this prospective cohort study, we found a favourable role of food
folate and fortified folic acid intake in HNC development. This
association was consistent across subsites of HNC, especially for
laryngeal cancer cases. The favourable role of folate intake showed
no deviation from a multiplicative model with smoking
and drinking, and was consistent across strata of known confounders.
To date, nine case-control studies (McLaughlin et al, 1988; De
Stefani et al, 1999; Negri et al, 2000; Weinstein et al, 2002; Bidoli
et al, 2003; Pelucchi et al, 2003; Suzuki et al, 2007; Aune et al, 2011;
Tavani et al, 2012) and one pooled analysis of case-control studies
(Galeone et al, 2015) have evaluated the association between folate
intake and the risk of HNC or its subsites. Only one study from the
USA evaluated the impact of folate intake on the risk of oral cavity
and pharyngeal cancer, including 871 cases, and reported no
association (McLaughlin et al, 1988). An Uruguayan study also
reported no association between folate intake and upper aero-
digestive tract (UADT) cancer risk (De Stefani et al, 1999). All
other studies reported a favourable effect of folate intake on the
risk of HNC or its subsites. In the study for Puerto Rico (Weinstein
et al, 2002), including 341 oral cavity and pharyngeal cases, a
favourable role of folate from fruit was observed, but no
associations were observed in other sources. Additionally, a more
recent Uruguayan study (Aune et al, 2011), including 283 oral
cavity and pharyngeal and 281 laryngeal cases, found an
interaction of folate intake with smoking status on UADT cancer
risk. Smoking induces deactivation of folate coenzymes and
vitamin B12 and results in folate deficiency (Heimburger, 1992).
These folate deficiency levels were also observed in buccal mucosa
among smokers (Piyathilake et al, 1992). In addition, an Italian
multi-centre study (Tavani et al, 2012), including 1467 oral cavity
and pharyngeal and 851 laryngeal cases, reported a decreased HNC
risk associated with folate intake. The OR for the highest vs the
lowest of intake was 0.37 for oral cavity and pharynx, and 0.55 for
larynx, with dose–response trends. In addition, the International
Head and Neck Cancer Epidemiology consortium study, a large-
scale pooled analysis including 5959 oral cavity and pharyngeal
cases, observed that higher folate intake was associated with a
decreased risk of oral cavity and pharyngeal cancer (OR: 0.65,
95%CI: 0.43–0.99 for the highest vs the lowest of quintile). This
association was apparently stronger among hospital-based study
than population-based study (Galeone et al, 2015). Additionally,
six studies have investigated serum or plasma folate levels to
compare between HNC cases and controls (Almadori et al, 2002;
Raval et al, 2002; Almadori et al, 2005; Eleftheriadou et al, 2006;
Gorgulu et al, 2010; Fanidi et al, 2015). They reported on a
significant decreased serum or plasma folate level among HNC
cases relative to controls. The European Prospective Investigation
into Cancer and Nutrition (EPIC) study reported that higher levels
of folate was associated with a decreased HNC risk in a dose–
response manner (OR: 0.63, 95%CI: 0.35–1.16 for the highest vs the
lowest of quantile) (Fanidi et al, 2015). However, this result was
attenuated when cases were compared with additional unmatched
controls.
Mechanisms of folate intake on HNC risk have been previously
proposed. Folate deficiency contributes to the alteration of the
normal methylation process and imbalance in the steady-state
levels of DNA precursors, inducing aberrant DNA synthesis,
stability and repair, and chromosomal changes (Lamprecht and
Lipkin, 2003; Ulrich and Grady, 2010). Global and regional
hypomethylation and hypermethylation within the CpG islands of
specific gene promoters have been identified in HNCs (Hasegawa
et al, 2002; Smith et al, 2007). In addition, this may lead to proto-
oncogene activation and chromosomal instability (Smith et al,
2007). Folate-rich foods tend to have a high content of
antioxidants, and consequently higher folate intake may be an
indicator of a diet rich in fruit, vegetable, and a better general
lifestyle pattern (Bosetti et al, 2009). However, we carefully
adjusted by total fruit and vegetable intake in a multivariate
analysis. In addition, we included other micronutrients, including
vitamin B6, vitamin B12, vitamin C, vitamin E, and carotenoids, in
multivariate analysis, and a decreased HR of food folate intake was
consistent after adjustment by these factors.
Alcohol drinking induces to modification of folate level (Bailey,
1990). Alcohol drinking leads to reduced folate absorption,
increased folate excretion, and inhibited methionine synthase in
one-carbon metabolism (Barak et al, 1987; Mason and Choi, 2005).
In this study, we detected no effect modification and interaction
between alcohol and folate intake on HNC risk. We found two
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studies which evaluated the interaction between alcohol drinking
and folate intake on HNC risk (Shanmugham et al, 2010; Matsuo
et al, 2012). The Nurse’s Health Study, a prospective cohort of
87 621 women and 147 incident oral cancer cases, observed an
interaction between alcohol and folate intake (P-value¼ 0.02). The
relative risk of highest alcohol drinking and low folate intake vs
never drinking and high folate intake was 3.36 (95% CI: 1.57–7.20).
Since our highest tertile of alcohol drinking was relatively low, we
might explain this inconsistency in this study.
We found no association with supplemental folic acid on HNC
risk. A recent meta-analysis, including 13 randomised trials of folic
acid supplementation and almost 50 000 individual data, reported
that folic acid supplementation does not substantially increase
incidence of site-specific cancer during the first 5 years of
supplementation (Vollset et al, 2013). However, dietary fortifica-
tion involves doses of folic acid that are an order of magnitude
lower than the doses studied in these trials. In addition, our data on
supplemental folic acid were only derived from recent use (current
or 2 year ago). But, our findings are also consistent with a previous
report on pancreatic cancer in PLCO study (Oaks et al, 2010).
Our study has several strengths. With the prospective design,
the questionnaire data were collected before cancer diagnosis.
Table 1. Characteristics of the PLCO cohort and the head and neck cancer cases
Cohort Cases
Characteristics No. of participants % No. of cases %
Total 101 700 186
Age
p59 years 34 950 35 63 34
60–64 years 31 742 31 60 32
65–69 years 22 526 22 44 24
X70 years 12 482 12 19 10
Sex
Male 49 460 49 150 81
Female 52 240 51 36 19
BMI
p24.9 kgm 2 33 737 33 63 34
X25.0 kgm 2 66 630 66 119 64
Missing 1333 1 4 2
Education
pHigh school 42 916 42 81 44
XSome college 58 587 58 105 56
Missing 197 0 0 0
Race
White, Non-Hispanic 92 483 91 168 90
Other 9217 9 18 10
Pack-year cigarette smoking
Never 48 544 48 36 19
o20 19 239 19 25 13
X20 32 761 32 124 67
Missing 1156 1 1 1
Alcohol drinking intensity (g per day)
Never 27 744 28 43 23
Q1 (o4.1) 36 976 36 43 23
Q2 (X4.1) 36 980 36 100 54
Pipe smoking
Never 86 543 85 146 78
Former 13 336 13 35 19
Current 937 1 5 3
Missing 884 1 0 0
Cigar smoking
Never 88 217 87 147 79
Former 10 820 10 31 17
Current 1678 2 7 4
Missing 985 1 1 0
Non-alcohol total energy (kcal per day)
Mean±s.d. 1670.91±698.09 1767.20±734.39
Total vegetable intake (g per day)
Mean±s.d. 284.03±186.37 263.72±162.46
Total fruit intake (g per day)
Mean±s.d. 273.91±217.84 212.31±281.97
Primary site
Oral cavity 81 44
Oropharynx 18 10
Hypopharynx 10 5
NOS 1 0
Larynx 76 41
Abbreviations: BMI¼body mass index; NOS¼oral cavity or pharynx not otherwise specified; PLCO¼ prostate, lung, colorectal, and ovarian cancer screening trial; s.d.¼ standard deviation.
BRITISH JOURNAL OF CANCER Impact of folate intake on the risk of HNC in the PLCO cohort
4 www.bjcancer.com |DOI:10.1038/bjc.2017.383
Table 2. Dietary folate intake and the risk of head and neck cancer or subsites in the PLCO cohort
Head and neck Oral cavity and Pharynx Larynx
Nutrients Cohort Cases HRa 95% CI P-value Cases HRa 95% CI P-value Cases HRa 95% CI P-value
Total folate (lg per day)
Q1 (o375.91) 25 424 59 1.00 — — 35 1.00 — — 24 1.00 — —
Q2 (X375.91 to o611.80) 25 426 52 0.91 0.62–1.35 0.643 24 0.65 0.38–1.12 0.119 27 1.33 0.75–2.38 0.329
Q3 (X611.80 to o780.26) 25 422 36 0.71 0.47–1.09 0.121 25 0.74 0.44–1.26 0.268 11 0.64 0.31–1.33 0.234
Q4 (X780.26) 25 428 39 0.72 0.45–1.16 0.183 25 0.64 0.35–1.18 0.157 14 0.85 0.40–1.82 0.676
Ptrend 0.090 0.220 0.261
Food folate (lg per day)
Q1 (o261.36) 25 425 61 1.00 — — 30 1.00 — — 30 1.00 — —
Q2 (X261.36 to o350.41) 25 422 33 0.47 0.30–0.73 0.001 22 0.65 0.36–1.16 0.143 11 0.30 0.15–0.63 0.001
Q3 (X350.41 to o461.90) 25 427 54 0.64 0.41–1.01 0.056 32 0.83 0.45–1.50 0.532 22 0.50 0.25–1.00 0.051
Q4 (X461.90) 25 426 38 0.35 0.18–0.67 0.002 25 0.52 0.23–1.22 0.132 13 0.21 0.07–0.62 0.005
ptrend 0.009 0.265 0.013
Natural folate (lg per day)
Q1 (o170.22) 25 425 51 1.00 — — 29 1.00 — — 21 1.00 — —
Q2 (X170.22 to o228.77) 25 422 45 0.89 0.57–1.37 0.592 29 0.91 0.52–1.59 0.746 16 0.92 0.45–1.87 0.818
Q3 (X228.77 to o304.99) 25 426 47 0.93 0.56–1.55 0.788 24 0.70 0.36–1.35 0.287 23 1.55 0.70–3.40 0.279
Q4 (X304.99) 25 427 43 0.88 0.43–1.79 0.723 27 0.69 0.28–1.71 0.425 16 1.41 0.46–4.28 0.548
ptrend 0.772 0.309 0.331
Fortified folic acid (lg per day)
Q1 (o71.20) 25 421 49 1.00 — — 25 1.00 — — 23 1.00 — —
Q2 (X71.20 to o109.89) 25 428 47 0.91 0.61–1.38 0.665 25 0.96 0.54–1.68 0.877 22 0.90 0.50–1.65 0.744
Q3 (X109.89 to o163.35) 25 421 55 0.95 0.63–1.44 0.810 35 1.22 0.70–2.11 0.482 20 0.72 0.38–1.39 0.330
Q4 (X163.35) 25 430 35 0.49 0.30–0.82 0.006 24 0.70 0.37–1.35 0.290 11 0.32 0.14–0.73 0.007
ptrend 0.014 0.473 0.008
Supplemental folic acid (lg per day)
Q1 (¼0) 38 080 88 1.00 — — 53 1.00 — — 35 1.00 — —
Q2 (X0 to o400) 15 767 26 0.86 0.56–1.34 0.513 11 0.63 0.33–1.18 0.148 14 1.26 0.68–2.35 0.468
Q3 (X400) 47 853 72 0.81 0.59–1.11 0.196 44 0.75 0.50–1.12 0.155 27 0.89 0.53–1.47 0.644
ptrend 0.194 0.153 0.669
Abbreviations: CI¼ confidence interval; HR¼ hazard ratios; PLCO¼prostate, lung, colorectal, and ovarian cancer screening trial.
aAdjusted by age, sex, body mass index, education level, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total
energy, total vegetable and fruit intake.
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Figure 1. Hazard ratios (HRs) of head and neck cancer, and corresponding confidence intervals (95% CIs), according to pack-year of cigarette
smoking and food folate intake (mg per day). The HRs were derived from Cox proportional hazard models, adjusting for age, sex, body mass
index, education, race/ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol
total energy, total vegetable and fruit intake. The number of cases and controls within each category was indicated below the corresponding HR
as: ‘number of cases: number of cohorts’. We found no interaction between smoking and food folate intake on HNC risk.
Impact of folate intake on the risk of HNC in the PLCO cohort BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.383 5
Age<65
BMI<25 kg m–2
BMI25 kg m–2
EducationHigh school
EducationSome college
Age65
Male
Q2 0.48 (0.28–0.83)
0.64 (0.36–1.11)
0.37 (0.17–0.82)
0.45 (0.21–0.97)
0.68 (0.31–1.47)
0.32 (0.10–1.04)
0.53 (0.32–0.87)
0.63 (0.38–1.04)
0.34 (0.16–0.69)
0.28 (0.09–0.89)
0.89 (0.30–2.61)
0.53 (0.10–2.90)
0.35 (0.16–0.78)
0.48 (0.22–1.05)
0.47 (0.17–1.31)
0.58 (0.34–1.00)
0.77 (0.44–1.36)
0.32 (0.14–0.77)
0.49 (0.26–0.94)
0.55 (0.28–1.09)
0.28 (0.10–0.78)
0.45 (0.24–0.83)
0.75 (0.41–1.37)
0.44 (0.18–1.03)
0.934
0.913
0.743
0.817
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8 3
Q3
Q4
Q2
Q3
Q4
Q2
p interaction
p interaction
p interaction
p interaction
Q3
Q4
Q2
Q3
Q4
Q2
Q3
Q4
Q2
Q3
Q4
Q2
Q3
Q4
Q2
Q3
Q4
Female
Figure 3. Impact of higher quartiles of food folate intake (Q2, X261.36 to o350.41mg per day; Q3, X350.41 to o460.90mg per day; Q4,
X460.90mg per day) on HNC risk compared to the lowest quartiles of food folate intake (Q1, o261.36mg per day) according to selected
covariates. The hazard ratios (HRs) were estimated from Cox proportional hazard models, adjusting for age, sex, body mass index, education, race/
ethnicity, pipe smoking status, cigar smoking status, pack-year cigarette smoking, alcohol drinking intensity, non-alcohol total energy, total
vegetable and fruit intake. We found no interaction between selected covariates and total fibre intake on HNC risk.
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Figure 2. Hazard ratios (HRs) of head and neck cancer, and corresponding confidence intervals (95% CIs), according to alcohol drinking intensity
(g per day) and food folate intake (mg per day). The HRs were derived from Cox proportional hazard models, adjusting for age, sex, body mass
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Thus, we can exclude the possibility of recall bias due to cancer
outcome. We carefully adjusted for known confounders associated
with HNC risk, including tobacco smoking, alcohol drinking and
the intake of total fruit and vegetable. In addition, we were able to
evaluate several types of dietary folate intake including fortified
and supplemental folic acid.
Our sample size of HNC cases was limited; thus, statistical
power was not so strong particularly for subsite analysis. However,
this is the largest prospective cohort study to date. The time
elapsed between exposure data collection and disease incidence
may lead to some underestimate of the real association. We were
unable to consider possible changes in diet between interview and
diagnosis. We did not have information on relevant gene variants
in one-carbon metabolism and HPV infection. Since these alleles
are randomly assigned at the time of gamete formation, the
distribution of alleles in our cohort is unlikely to confound the
protective role of folate intake on HNC development (Smith and
Ebrahim, 2003). In addition, since we would not expect HPV
infection to be related specifically to folate intake, HPV infection
status does not meet the properties of a confounder. In any case
our data set included only 18 oropharyngeal cancers which was
associated with HPV infection. When we divided HNC cases into
subsites, we also considered the impact of folate intake on
oropharyngeal cases only. We found a similar decreased trend on
oropharyngeal cases.
In summary, our findings provided evidence of the protective
role of dietary folate on HNC development.
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